Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award

Published on by TOT Awards

Dr. Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award

Iran University of Medical Sciences | Iran

Dr. Milad Shirvaliloo is a physician-scientist and accomplished biomedical researcher recognized for his extensive contributions to the fields of epigenetics, nanomedicine, and cancer biology. His scholarly work bridges molecular medicine and translational research, focusing primarily on histone modifications, non-coding RNAs, and nanoparticle-based therapeutic interventions in cancer and pulmonary diseases. With a robust publication record of more than 40 peer-reviewed scientific articles and a book chapter, Dr. Shirvaliloo’s research has gained wide recognition in the global academic community. His studies have illuminated novel mechanisms of epigenetic regulation, particularly in the context of lung disease, viral infection, and tumor angiogenesis, advancing understanding in both basic and clinical medicine. On Google Scholar, he has achieved 1,074 citations (1,071 since 2020) with an h-index of 19 and an i10-index of 30, while Scopus indexes 819 citations across 717 documents with an h-index of 16, demonstrating his strong and consistent research influence. As an editorial board member of high-impact journals such as Epigenomics and Molecular and Cellular Biochemistry, and as a reviewer for over 60 Web of Science–indexed journals, he has played a significant role in advancing scientific communication and maintaining research integrity. Dr. Shirvaliloo’s dedication to innovative biomedical inquiry and his outstanding contributions to the field have earned him recognition for the Best Researcher Award, honoring his commitment to excellence, scientific leadership, and impactful discovery in medical research.

Publication Profile

Scopus | Orcid | Google Scholar

Featured Publications

  • Heris, R. M., Shirvaliloo, M., Abbaspour-Aghdam, S., Hazrati, A., Shariati, A., Youshanlouei, H. R., et al. (2022). The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment. Stem Cell Research & Therapy, 13(1), 371.

  • Sheervalilou, R., Shirvaliloo, M., Dadashzadeh, N., Shirvalilou, S., Shahraki, O., Pilehvar-Soltanahmadi, Y., et al. (2020). COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease. Journal of Cellular Physiology, 235(12), 8873–8924.

  • Aghbash, P. S., Eslami, N., Shirvaliloo, M., & Baghi, H. B. (2021). Viral coinfections in COVID-19. Journal of Medical Virology, 93(9), 5310–5322.

  • Shirvalilou, S., Khoei, S., Esfahani, A. J., Kamali, M., & Shirvaliloo, M. (2021). Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: A systematic review. Journal of Neuro-Oncology, 152(3), 419–428.

  • Razlansari, M., Jafarinejad, S., Rahdar, A., Shirvaliloo, M., Arshad, R., Fathi-Karkan, S., et al. (2023). Development and classification of RNA aptamers for therapeutic purposes: An updated review with emphasis on cancer. Molecular and Cellular Biochemistry, 478(7), 1573–1598.